AngioGenex, Inc.
425 Madison Avenue 48th Street
9th Floor Suite 902
New York,
NY 10017
United States - Map
Phone: 212-874-6008
Fax: 212-874-5027
Web Site: http://www.angiogenex.com
| AngioGenex, Inc., a development stage biopharmaceutical company, engages in the discovery and development of products for the treatment, diagnosis, and prognosis of cancer. Its development programs focus on the discovery and development of orally active anti-cancer drugs that act by modulating the action of the Id proteins; the measurement of Id proteins in tumors and blood to create products for the diagnosis and prognosis of cancer; the generation of proof-of-concept data in relevant preclinical models to establish that modulation of Id genes and proteins is useful to treat non-oncologic diseases; and collaborating in respect to treatments of diseases in which blood vessel proliferation is desirable. The companys pre-clinical lead drug candidates include AGX8 and AGX51, which are proprietary small molecule inhibitors of the Id proteins. AngioGenex was founded in 1999 and is based in New York, New York. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Richard A. Salvador Ph.D., 80
Co-Founder, Chairman and Pres |
$
0 | N/A | Dr. William A. Garland Ph.D., 63
Chief Exec. Officer, Chief Operating Officer, VP |
$
0 | N/A | Mr. Michael M. Strage Esq, 50
Co-Founder, VP of Bus. Devel., VP of Investor Relations, VP of Corp. Communications |
$
0 | N/A | Mr. Martin F. Murray MBA, CPA, 42
Chief Financial Officer, Principal Accounting Officer, Sec., Treasurer, Controller |
$
0 | N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.29% Nasdaq 0.00%
Profile
